Quote & Headlines
Market Currents
StockTalk
Description
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
340 people get AMRI articles and Market Currents by email alert.
Get email alerts on AMRI »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Q1 2013 Value Stock Screen Performance SummaryJae Jun • Mon, Apr 8 -
-
-
AMRI Turnaround At Inflection PointLen Zehr • Wed, Jun 6, 2012 -
-
-
-
-
-
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
Q1 2013 Value Stock Screen Performance SummaryJae Jun • Mon, Apr 8
-
-
-
-
-
-
-
-
-
-
-
-
-
Albany Molecular Research Q4 2008 Earnings Call TranscriptMon, Feb 9, 2009
-
Albany Molecular Research, Inc. Q3 2008 Earnings Call TranscriptTue, Nov 18, 2008
-
Albany Molecular Research, Inc. Q2 2008 Earnings Call TranscriptSat, Aug 30, 2008
-
Albany Molecular Research Inc. Q1 2008 Earnings Call TranscriptMon, May 5, 2008
-
Albany Molecular Research, Inc. Q4 2007 Earnings Call TranscriptMon, Feb 11, 2008
-
at MarketWatch.com (Dec 23, 2011)
-
at MarketWatch.com (May 20, 2011)
-
at CNBC.com (Nov 22, 2010)
-
at MarketWatch.com (Aug 24, 2010)
AMRI vs. ETF Alternatives
Company Description
Currently, there's no company description for AMRI.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Tuesday, May 7, 12:52 PM
Midday top 10 gainers: FSGI +28%. ARCI +27%. ININ +18%. MELI +18%. NLS +18%. PRTS +18%. REED +16%. PODD +14%. LAS +12%. MKTG +12%.
Midday top 10 losers: DCO -27%. RKUS -25%. GNK -24%. CUTR -23%. ARUN -22%. SNTA -15%. AMRI -12%. PIKE -12%. TA -12%. PTRY -11%. Comment! [On the Move] - Tuesday, May 7, 8:46 AM More on Albany Molecular Research's (AMRI) Q1: Contract revenue and margins rise 9% and 19% Y/Y respectively with the latter driven by improvements in the performance of the discovery and large scale manufacturing segments. The company reaffirms its FY13 revenue guidance (~12% growth) and ups its EPS outlook to $0.52-0.65 per share. (PR) Comment! [Healthcare, Earnings]
- Tuesday, May 7, 8:09 AM Albany Molecular (AMRI): Q1 EPS of $0.23. Revenue of $59.4M (+11% Y/Y). Comment! [Earnings, Breaking News]
- Sunday, April 14, 10:43 PM The rest of the top 25 June additions to the Russell 2000 expected by Credit Suisse: GNMK, AVIV, FBC, TTS, UNXL, GARS, REMY, BNCN, CBK, VRNG, LFVN, GTN, NLS, ENT, AMRI, POWR, DCO, INSM, CUTR, PPBI. "Very few of the bigger adds are owned by actively managed small cap funds," notes CS. Comment! [Quick Ideas]
-
Wednesday, February 13, 12:45 PM
Midday top 10 gainers: RSOL +76%. RCON +27%. TRLA +25%. PRLB +24%. RPXC +22%. PRO +18%. ICAD +17%. PES +13%. AMRI +12%. VG +11%.
Midday top 10 losers: LTRE -21%. EZCH -21%. RATE -19%. RAX -18%. CLF -18%. MPG -17%. FBN -17%. NAII -16%. ATOS -14%. ZN -13%. Comment! [On the Move] -
Tuesday, February 12, 12:45 PM
Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move] - Tuesday, February 12, 12:20 PM Albany Molecular Research (AMRI +18%) surges after its FQ3 easily blows out estimates this morning. Contract revenue was $59.1M, up 50% from the prior-year period with sequential revenue improvement in Discovery and Large Scale Manufacturing services. Contract margin jumped to 18% from 2% in the prior-year period. The company also forecast an upbeat Q4, now expecting an EPS of $0.08 - $0.12, better than the Street view of $0.06. Comment! [Earnings, On the Move]
- Tuesday, February 12, 8:15 AM Albany Molecular (AMRI): Q4 EPS of $0.17 beats by $0.08. Revenue of $67.2M (+44% Y/Y) beats by $10.71M. (PR) Comment! [Earnings, Breaking News]
-
Tuesday, January 22, 12:45 PM
Midday top 10 gainers: PBIB +32%. DQ +18%. TECUA +18%. ONP +17%. USEG +17%. RDCM +17%. CIMT +14%. BOX +14%. MTRX +12%. PRCP +12%.
Midday top 10 Losers: CALI -12%. OIBR -12%. BVX -10%. DOM -9%. ARNA -8%. IIVI -8%. AMRI -8%. UPI -8%. IPXL -8%. EXFO -7%. Comment! [On the Move] - Tuesday, November 20, 2012, 11:45 AM AngioDynamics (ANGO -0.5%) says its CFO, Joseph Gersuk, is stepping down in late January. Mr. Gersuk will be succeeded by Mark T. Frost, whose most recent position was as finance chief of Albany Molecular Research (AMRI +5.7%). Comment! [Healthcare]
- Tuesday, November 6, 2012, 10:30 AM Albany Molecular Research (AMRI +11%) pops after beating on its Q3 bottom line this morning. Total sales were up 11.2% Y/Y on stronger royalty and contract revenues, particularly in its large-scale manufacturing segment. The company also boosts its outlook for FY12 as well as Q4. It now sees FY12 earnings coming in between $0.10 and $0.16 per share, towards the top-end of the Street's $0.12 consensus, and for Q4, its EPS is targeted to be $0.08 to $0.12, also better than the Street view of $0.06. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, November 6, 2012, 9:17 AM Albany Molecular Research (AMRI): Q3 EPS of $0.00 beats by $0.02. Revenue of $55.8M (+11.2% Y/Y). (PR) Comment! [Earnings, Healthcare]
- Wednesday, August 1, 2012, 8:38 AM Albany Molecular Research (AMRI): Q2 EPS of $0.06 beats by $0.04. Revenue of $50M (-7.2% Y/Y) misses by $2M. (PR) Comment! [Earnings]
- Wednesday, May 9, 2012, 8:22 AM Albany Molecular Research (AMRI): Q1 EPS of $0.02 misses by $0.03. Revenue of $53.7M (-5.6% Y/Y) beats by $1.5M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, February 7, 2012, 8:15 AM Albany Molecular Research (AMRI): Q4 EPS of -$0.19 misses by $0.05. Revenue of $46.6M (-4.1% Y/Y) misses by $2M. Shares -8.8% premarket. (PR) Comment! [Earnings, Healthcare, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES